Sun Pharma to buy concert for $576 m - Business News: Latest News & Videos about market and economy | Trendmergers

Breaking

Post Top Ad

Post Top Ad

Sun Pharma to buy concert for $576 m

Concert has pioneered the use of deuterium (a hydrogen isotope) in medicinal chemistry and has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor that blocks Janus kinases JAK1 and JAK2 for the treatment of baldness. Concert has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe.

from Industry-Economic Times
Read The Rest:economictimes...

Post Top Ad